

Références – Crestor

1. Monographie du médicament Crestor (rosuvastatin). Astra Zeneca, Mississauga (Ontario), février 2003.
2. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. *Drugs* 2002; 62:2075-85. (document électronique)
3. Chong PH, Yim BT. Rosuvastatin for the treatment of patients with hypercholesterolemia. *Ann Pharmacother* 2002;36(1):93-101. (document électronique)
4. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. *Am J Cardiol* 2001;88:504-8. (document électronique)
5. Davidson M, Ma P, Stein EA *et al.* Comparison of effects of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. *Am J Cardiol* 2002;89:268-75. (document électronique)
6. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolemia patients: a randomized, double-blind study. *J Cardiovascular Risk* 2001;8:383-90. (document papier)
6. Brown WV, Bays HE, Hassman DR *et al.* Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52 week trial. *Am Heart J* 2002; 144:1036-43. (document papier)
7. Olsson AG, Istad H, Lurila O *et al.* Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. *Am Heart J* 2002; 144:1044-51. (document papier)
8. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. *Am J Cardiol* 2003;91:33-41. (document papier)
9. Hunninghake DB, Chitra RR, Simonson G *et al.* Treatment of hypertriglyceridemic patients with rosuvastatin. *Diabetes* 2001;50(suppl 2):A143. (document papier)
10. Stein E, Strutt KL, Miller E. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. *J Am Coll Cardiol* 2001;37 (suppl A):292. (document papier)
11. Anon. Managing dyslipidemia: Update on guidelines and pharmacotherapy. *J Am Pharm Assoc* 2002;42(5)suppl 5:S36-7. (document papier)
12. Chong PH. Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. *Ann Pharmacother* 2002;36(12):1907-17. (document électronique)
13. Fodor JG, Frohlich JJ, Genest JGG, McPherson PR. Recommendations for the management and treatment of dyslipidemia. *CMAJ* 2000;162(10):1441-7. (document électronique)
14. Anon. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Institute of Health, May 2001, NIH Publication Number 01-3670. (document électronique)
15. Stein EA. Introduction: Rosuvastatin – an efficacy assessment based on pooled trial data. *Am J Cardiol* 2003;91(5A):1-2C. (document électronique)
16. Blasseto JW, Stein EA, Brown WV *et al.* Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. *Am J Cardiol* 2003;91(5A):3-10C. (document électronique)
17. Shepherd J, Hunninghake DB, Barter P *et al.* Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. *Am J Cardiol* 2003;91(5A):11-19C. (document électronique)
18. Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and Apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. *Am J Cardiol* 2003;91(5A):20-4C. (document électronique)
19. Ballantyne CM, Stein EA, Paoletti R *et al.* Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. *Am J Cardiol* 2003;91(5A):25-8C.
20. Repchinsky C, editor. *Compendium of Pharmaceutical and Specialties*, 38th ed. Canadian Pharmacists Association. 2003, Ottawa.